Preventive Treatment of Migraine

Candice M. Todd; Claire H. Sandoe; Christine Lay

doi:10.1055/a-1933-4366

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2022; 42(04): 503-511
DOI: 10.1055/a-1933-4366

Review Article

Preventive Treatment of Migraine

Candice M. Todd

¹Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada

,

Claire H. Sandoe

¹Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada

,

Christine Lay

¹Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada

› Institutsangaben

Abstract

Migraine significantly impacts individuals from all walks of life and from all around the globe. Chronic or high-frequency episodic migraine has similar disability and burden on the healthcare system and can be challenging to manage. The focus of this article is to provide an outline of the available pharmacological and nonpharmacological evidence-based strategies that clinicians can employ to build a “toolbox” for their patients.

Keywords

migraine - prevention - prophylaxis - chronic headache

Volltext

Referenzen

References
1 Rasmussen BK. Epidemiology of headache. Cephalalgia 2001; 21 (07) 774-777
2 Dodick DW, Loder EW, Manack Adams A. et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 2016; 56 (05) 821-834
3 Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB. Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. [published online ahead of print, October 14, 2020] Headache 2020;
4 Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability. Headache 2016; 56 (08) 1280-1289
5 Ishii R, Schwedt TJ, Dumkrieger G. et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 2021; 61 (07) 992-1003
6 Ailani J, Burch RC, Robbins MS. Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 2021; 61 (07) 1021-1039
7 Hepp Z, Dodick DW, Varon SF. et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 2017; 37 (05) 470-485
8 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1337-1345
9 Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med 2002; 346 (04) 257-270
10 Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288 (03) 351-357
11 Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31 (05) 333-340
12 Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. A double-blind crossover study. JAMA 1984; 252 (18) 2576-2580
13 Smith HS, Pappagallo M, Stahl SM. Essential Pain Pharmacology: The Prescriber's Guide. Timolol. Cambridge: Cambridge University Press; 2012: 454-456
14 Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. Headache 1986; 26 (10) 490-493
15 Dodick DW, Freitag F, Banks J. et al; CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31 (03) 542-559
16 By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019; 67 (04) 674-694
17 Richardson K, Fox C, Maidment I. et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2019; 367: l6213
18 Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache 2018; 58 (Suppl. 03) 218-229
19 Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (02) 144-152
20 Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107 (01) 44-48
21 Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol 2019; 21 (04) 18
22 Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician 2019; 99 (01) 17-24
23 Silberstein SD, Lipton RB, Dodick DW. et al; Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47 (02) 170-180
24 Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27 (07) 814-823
25 Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23 (08) 820-824
26 Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn) 2015; 21 (4 Headache): 973-989
27 Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006; 82 (01) 23-28
28 Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis – an open label study. Eur J Neurol 2007; 14 (06) 701-703
29 Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60 (02) 444-450
30 Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs 2008; 22 (10) 877-886
31 Maasumi K, Tepper SJ, Kriegler JS. Menstrual migraine and treatment options: review. Headache 2017; 57 (02) 194-208
32 Martinelli D, Arceri S, De Icco R. et al. BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. Cephalalgia 2022; 42 (02) 170-175
33 Begasse de Dhaem O, Gharedaghi MH, Rizzoli P. Modifications to the PREEMPT protocol for onabotulinumtoxinA injections for chronic migraine in clinical practice. Headache 2020; 60 (07) 1365-1375
34 Diener HC. CGRP-targeted drugs for migraine: still many uncertainties. Lancet Neurol 2022; 21 (03) 209-210
35 Tepper SJ, Sheikh HU, Dougherty CO. et al. Erenumab dosage for migraine prevention: an evidence-based narrative review with recommendations. Headache 2022; 62 (04) 420-435
36 Tepper SJ, Lucas S, Ashina M. et al. Temporal response patterns to erenumab in patients with chronic migraine. Cephalalgia 2019; 39 (01) 211-212
37 Barbanti P, Aurilia C, Cevoli S. et al; EARLY Study Group. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 2021; 61 (09) 1351-1363
38 Dodick DW, Tepper SJ, Ailani J. et al. Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache 2021; 61 (09) 1411-1420
39 Sessa M, Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35 (02) 215-227
40 McAllister P, Lamerato L, Krasenbaum LJ. et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain 2021; 22 (01) 156
41 Silberstein SD, Dodick DW, Bigal ME. et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377 (22) 2113-2122
42 Pellesi L, De Icco R, Al-Karagholi MA, Ashina M. Reducing episodic cluster headaches: focus on galcanezumab. J Pain Res 2020; 13: 1591-1599
43 Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91 (24) e2211-e2221
44 Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018; 75 (09) 1080-1088
45 Ashina M, Saper J, Cady R. et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40 (03) 241-254
46 Dodick DW, Lipton RB, Silberstein S. et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 2019; 39 (09) 1075-1085
47 Lipton RB, Goadsby PJ, Smith J. et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94 (13) e1365-e1377
48 Silberstein S, Diamond M, Hindiyeh NA. et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain 2020; 21 (01) 120
49 Martin V, Tassorelli C, Ettrup A, Hirman J, Cady R. Eptinezumab for migraine prevention in patients 50 years or older. Acta Neurol Scand 2022; 145 (06) 698-705
50 Winner PK, McAllister P, Chakhava G. et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 2021; 325 (23) 2348-2356
51 Edvinsson L. Oral rimegepant for migraine prevention. Lancet 2021; 397 (10268): 4-5
52 Croop R, Lipton RB, Kudrow D. et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397 (10268): 51-60
53 Singh A, Balasundaram MK. Atogepant for migraine prevention: a systematic review of efficacy and safety. Clin Drug Investig 2022; 42 (04) 301-308
54 Toni T, Tamanaha R, Newman B. et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci 2021; 42 (12) 5373-5376
55 Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: Is there a rationale?. Headache 2020; 60 (06) 1056-1065
56 Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine. Pain Med 2021; 22 (08) 1857-1863
57 Seng EK, Gosnell I, Sutton L, Grinberg AS. Behavioral management of episodic migraine: maintaining a healthy consistent lifestyle. Curr Pain Headache Rep 2022; 26 (03) 247-252
58 Evcili G, Utku U, Öğün MN, Özdemir G. Early and long period follow-up results of low glycemic index diet for migraine prophylaxis. Agri 2018; 30 (01) 8-11
59 Ferrara LA, Pacioni D, Di Fronzo V. et al. Low-lipid diet reduces frequency and severity of acute migraine attacks. Nutr Metab Cardiovasc Dis 2015; 25 (04) 370-375
60 Turner DP, Lebowitz AD, Chtay I, Houle TT. Headache triggers as surprise. Headache 2019; 59 (04) 495-508
61 Kumar A, Bhatia R, Sharma G. et al. Effect of yoga as add-on therapy in migraine (CONTAIN): a randomized clinical trial. Neurology 2020; 94 (21) e2203-e2212
62 Smitherman TA, Kuka AJ, Calhoun AH. et al. Cognitive-behavioral therapy for insomnia to reduce chronic migraine: a sequential Bayesian analysis. Headache 2018; 58 (07) 1052-1059
63 Creswell JD, Lindsay EK, Villalba DK, Chin B. Mindfulness training and physical health: mechanisms and outcomes. Psychosom Med 2019; 81 (03) 224-232
64 Simshäuser K, Lüking M, Kaube H, Schultz C, Schmidt S. Is mindfulness-based stress reduction a promising and feasible intervention for patients suffering from migraine? A randomized controlled pilot trial. Complement Med Res 2020; 27 (01) 19-30
65 Seminowicz DA, Burrowes SAB, Kearson A. et al. Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes. Pain 2020; 161 (08) 1837-1846
66 Lagman-Bartolome AM, Lawler V, Lay C. Headache education active-waiting directive: a program to enhance well-being during long referral wait times. Headache 2018; 58 (01) 109-117
67 Schoenen J, Vandersmissen B, Jeangette S. et al. Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device (PREMICE): a multi-centre, randomized, sham-controlled trial. J Headache Pain 2013; 14 (Suppl 1): Epub 2013 Feb 21. PMCID: PMC3620126 184
68 Starling AJ, Tepper SJ, Marmura MJ. et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38 (06) 1038-1048
69 Schoenen J, Ambrosini A. Update on noninvasive neuromodulation for migraine treatment - vagus nerve stimulation. Prog Brain Res 2020; 255: 249-274
70 Diener HC, Goadsby PJ, Ashina M. et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019; 39 (12) 1475-1487
71 Coppola G, De Pasqua V, Pierelli F, Schoenen J. Effects of repetitive transcranial magnetic stimulation on somatosensory evoked potentials and high frequency oscillations in migraine. Cephalalgia 2012; 32 (09) 700-709
72 Nowaczewska M, Wiciński M, Osiński S, Kaźmierczak H. The role of vitamin D in primary headache - from potential mechanism to treatment. Nutrients 2020; 12 (01) 243
73 von Luckner A, Riederer F. Magnesium in migraine prophylaxis - Is there an evidence-based rationale? A systematic review. Headache 2018; 58 (02) 199-209
74 Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16 (04) 257-263
75 Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1346-1353
76 Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44 (09) 885-890
77 Wells RE, Baute V, Wahbeh H. Complementary and integrative medicine for neurologic conditions. Med Clin North Am 2017; 101 (05) 881-893
78 Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. Investigators. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis – a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22 (07) 523-532
79 Lösche W, Mazurov AV, Heptinstall S, Groenewegen WA, Repin VS, Till U. An extract of feverfew inhibits interactions of human platelets with collagen substrates. Thromb Res 1987; 48 (05) 511-518
80 Parohan M, Sarraf P, Javanbakht MH, Ranji-Burachaloo S, Djalali M. Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Neurosci 2020; 23 (11) 868-875
81 Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63 (12) 2240-2244
82 Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007; 47 (03) 355-363